Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

200292 citationsJournal Article

Authors

rhIL-12 at 300 ng/kg by weekly i.p. injection is biologically active and adequately tolerated for Phase II studies.

Good health and well-being

Published in: PubMed

Volume 8, Issue 12, pp. 3686-95

Field-Weighted Citation Impact: 4.78